OPK
$1.12-0.05 (-4.27%)
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally.
Recent News
Barrington Lowers PT on OPKO Health (OPK), Keeps a Buy
OPKO Health, Inc. (NASDAQ:OPK) is one of the High-Flying Penny Stocks to Buy. On March 12, Barrington lowered the firm’s price target on OPKO Health, Inc. (NASDAQ:OPK) from $2.25 to $1.50 and maintained a Buy rating on the stock. The firm noted that although the company topped Street estimates for fiscal Q4 2025, the way […]
Here's Why You Should Hold OPK Stock in Your Portfolio for Now
OPK rides on RAYALDEE strength and partnerships, but revenue decline, losses, and reliance on a single drug cloud its near-term outlook.
OPK Q4 Earnings & Revenues Beat Estimates, Gross Margin Contracts
OPKO Health beats Q4 earnings and revenue estimates, but sales decline and gross margin narrows.
OPKO Health, Inc. Q4 2025 Earnings Call Summary
Moby summary of OPKO Health, Inc.'s Q4 2025 earnings call
OPKO Health Q4 Earnings Call Highlights
OPKO Health (NASDAQ:OPK) executives said the company exited 2025 with “tremendous momentum,” citing efforts to reposition its diagnostics business for a return to profitability, advance its ModeX therapeutic pipeline, use non-dilutive partnership funding to support R&D, and strengthen the balanc